A detailed history of State Street Corp transactions in Pds Biotechnology Corp stock. As of the latest transaction made, State Street Corp holds 111,833 shares of PDSB stock, worth $225,902. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111,833
Previous 130,533 14.33%
Holding current value
$225,902
Previous $382,000 11.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.93 - $4.23 $54,791 - $79,101
-18,700 Reduced 14.33%
111,833 $427,000
Q2 2024

Aug 14, 2024

SELL
$2.55 - $4.02 $1.09 Million - $1.72 Million
-426,787 Reduced 76.58%
130,533 $382,000
Q1 2024

May 15, 2024

BUY
$3.85 - $6.59 $20,358 - $34,847
5,288 Added 0.96%
557,320 $2.21 Million
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $186,009 - $309,858
47,091 Added 9.33%
552,032 $2.74 Million
Q3 2023

Nov 14, 2023

BUY
$4.8 - $6.4 $230,236 - $306,982
47,966 Added 10.5%
504,941 $2.55 Million
Q2 2023

Aug 14, 2023

BUY
$5.03 - $9.9 $1.78 Million - $3.51 Million
354,442 Added 345.69%
456,975 $2.3 Million
Q1 2023

May 15, 2023

BUY
$5.68 - $11.99 $42,600 - $89,925
7,500 Added 7.89%
102,533 $630,000
Q4 2022

Feb 14, 2023

BUY
$3.28 - $13.2 $45,264 - $182,160
13,800 Added 16.99%
95,033 $1.25 Million
Q2 2022

Aug 15, 2022

BUY
$3.05 - $6.68 $14,335 - $31,396
4,700 Added 6.14%
81,233 $297,000
Q1 2022

May 16, 2022

BUY
$4.78 - $8.43 $19,392 - $34,200
4,057 Added 5.6%
76,533 $474,000
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $73,720 - $136,325
9,500 Added 15.09%
72,476 $587,000
Q3 2021

Nov 15, 2021

BUY
$9.33 - $17.08 $35,454 - $64,903
3,800 Added 6.42%
62,976 $938,000
Q2 2021

Aug 16, 2021

BUY
$4.35 - $12.86 $257,415 - $761,003
59,176 New
59,176 $743,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $57.5M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.